Joseph Rutledge, MD
Interventional Pain Medicine · Lafayette, INNPI 1750709523
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by SPR Therapeutics, Inc at 51.6% of the total. Among interventional pain medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $138.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$49K
- Biotronik NRO, Inc.$21K
- Boston Scientific$6K
- Tersera Therapeutics LLC$6K
- Abbott$6K
- AbbVie$2K
- plus $6K from 38 others
What the payments were for
- Consulting fees$45,59248%
- Speaking & faculty fees$15,03316%
- Travel & lodging$15,44416%
- Food & beverage$19,58420%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRINT PNS System$48,423
- Prospera$19,282
- PRIALT$5,495
- WaveWriter Alpha Prime 16$1,794
- Proclaim Family of SCS IPGs$1,339
- mild Device Kit$879
- Proclaim IPG$818
- XEOMIN$598
- Neuromodulation Dspsbls and Accs$395
- GENERAL PAIN MANAGEMENT$378
- VANTA ADAPTIVESTIM$200
- ADAPTIVESTIM$173
- Evoke$141
- AIMOVIG$125
- WAVEWRITER ALPHA$120
- Octrode SCS Leads$109
- Axium INS DRG IPG$107
- SPECTRA WAVEWRITER$104
How this compares
$95,658 in reported general payments places this provider in the 95th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 51 | $40,593 |
| Nurtec OdtRimegepant Sulfate | 15 | $15,586 |
| QuliptaAtogepant | 11 | $12,008 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 580 | $11,445 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 78 | $11,268 |
| Buprenorphine | 27 | $6,674 |
| Gabapentin | 260 | $3,732 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 135 | $3,500 |
| Lidocaine | 25 | $3,062 |
| Pregabalin | 119 | $2,709 |
| Buprenorphine Hcl | 41 | $1,831 |
| Oxycodone Hcl | 74 | $1,506 |
| Celecoxib | 32 | $1,115 |
| Cephalexin | 156 | $1,072 |
| Tramadol Hcl | 225 | $1,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $28 | $40,59351 claims |
| PfizerNurtec Odt | $71 | $15,58615 claims |
| AbbVieQulipta | $1,871 | $12,00811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Lafayette
- Mohamad SebaiLafayette$10K
- Jennifer EmmertLafayette$3K
- Kelly GrottLafayette$2K
- Shelle SchumacherLafayette$735
- Joshua WellingtonCarmel$315K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.